A Study Of AL101 In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Official Title

A Phase 2, Open-Label, Single-Arm, Multi-Centre Study Of AL101 (BMS-906024) In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations

Summary:

This is a Phase 2, Simon 2-Stage optimal design, non comparative, open label, single-arm, multicentre study of AL101 in patients with recurrent or metastatic ACC who harbor NOTCH 1,2,3,4 activating mutations.

Trial Description

Primary Outcome:

  • Objective response rate (ORR; complete response [CR] and partial response [PR]) by RECIST v1.1
Secondary Outcome:
  • Frequency, duration and severity of adverse events (AEs) and serious adverse events (SAEs);

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society